A PROCESS FOR PRODUCING SUPPOSITORIES BY COMPRESSION AND SUPPOSITORIES OBTAINED BY THE PROCESS

Abstract: Suppositories which may have a considerably higher content of an active drug than ordinary suppositories, are produced by compressing a suppository mass, which contains a considerable amount of a polyethylene glycol having a molecular weight of at least 4000, preferably 6000. The polyethylene glycol constitutes 20-50 % by weight of the suppository mass, which moreover contains microcrystalline cellulose and/or other additives common in the production of drugs. The obtained suppositories are more convenient to store and use, easier to produce and considerably more concentrated with respect to active substance (up to 75 % by weight) than traditional melt-moulded suppositories.

Description: A process for producing suppositories by compression and suppositories obtained by the process The present invention concerns a special process for pro- ducing suppositories by compression, and the process of the invention is characterized by producing a suppository mixture granulate containing a considerably greater amount of active drug than ordinary suppositories as well as 20- 50% by weight of a polyethylene glycol having an average molecular weight of at least 4000, and producing the sup¬ positories in the same manner as tablets, i.e. by compres¬ sion, instead of by moulding. The invention moreover con¬ cerns the suppositories obtained by the process which have a considerably higher percentual content of active drug than ordinary suppositories. As will be known, suppositories are drugs intended for insertion into the rectum. They contain the active drug in a dosed amount and are produced by pressing, moulding or compression. They can also be produced in the form of cap¬ sules for controlled release of the active substance. Ordinarily suppositories are produced by moulding, the produced mass being melted using the least possible amount of heat, and then the liquid mass is poured into moulds having the desired nominal capacity. The suppositories produced by moulding are oblong and smooth, and they have a uniform appearance. Melting is in- tended to provide a uniform distribution of the drug in the basic mass, which, however, can be difficult to obtain because of sedimentation during hardening. However, traditional moulding is a time-consuming and slow process which involves considerable costs. Moulded suppo- sitories also have the drawback that too strong heating of certain suppository basic masses result in unstable modi¬ fications with a considerably reduced solidification point. It is well-known to use polyethylene glycols having ave¬ rage molecular weights of 4000-6000 or above as the main component in the basic mass for suppositories produced by traditional melting and moulding. Thus, the DE Offenle- gungsschrift 2 248 777 describes melt-moulded indomethacin suppositories whose basic mass contains such polyethylene glycols. An object of the invention is to provide a process enab- ling the production of suppositories having a high content of active drug, which are partly more convenient to store and are partly more convenieny to use and easier and cheaper to produce than traditional melt-moulded supposi¬ tories. This is achieved by the process of the invention which is characterized by the subject-matter stated in the charac¬ terizing portion of claim 1. It has previously been attempted to produce suppositories by compression or pressing, i.e. by traditional tabletting methods. However, these suppositories tend to form irre¬ gular rough surfaces, which makes them unpleasant to use for the patient. Moreover, in such a production method it has been found impossible to dose the drug in so high doses as is often desirable owing to the prescribed treat¬ ment. Thus, the EP publication 111 137 describes suppositories containing the drug indomethacin in a base consisting of polyethylene glycol having an average molecular weight of up to 35,000. It is stated that the content of the active drug may be up to 50% by weight, but preferably the con¬ tent is 2-40% by weight and in particular 2-26% by weight. All the examples in the publication concern rectal tablets having a content of indomethacin of 2.8 - 5.8% by weight and rectal capsules having a content of indomethacin of 5.25 - 10.5% by weight, i.e. rather low concentrations. Further, the suppositories thus known contain quite high amounts of polyethylene glycols, typically 1600-1730 mg per unit, which is a drawback, because it has been found that a content of polyethylene glycols in suppositories of 1 - 1.5 g per unit may cause bowel disorders. It has now surprisingly been found that a composition which can easily be compressed to suppositories by an ordinary tabletting method can be obtained by using a suitable amount, more particularly 20-50% by weight of a polyethylene glycol having an average molecular weight of at least 4000 in the suppository basic mass. The use of such a polyethylene glycol in the basic mass results in suppositories having a uniform appearance and having an extremely smooth and regular surface, which is moreover sufficiently slippery for the suppository to be inserted without difficulty. It is moreover possible in such suppo- sitories to incorporate up to 75% by weight of active drug, which is far above normal. Polyethylene glycols, more particularly mixtures of con¬ densation polymers of ethylene oxide and water, are also called "macrogols". Macrogols having average molecular weights of 200-700 are liquids, while macrogols having average molecular weights above 1000 vary in consistence from soft oily substances to hard wax-like solid sub¬ stances. The average molecular weight is stated as a number after the name. "Macrogol 6000", which it is pre¬ ferred to use according to the invention, thus has an ave- rage molecular weight of about 6000. The macrogols have the general formula H(CH 2 OCH 2 ) n OH where n is greater than or equal to 4. In "Macrogol 6000" n has an average value of between 158 and 204. It is a white or cream-coloured solid wax-like substance which is in the form of a powder or flakes. The melting point is 56-63 α C, i.e. considerably above the body temperature. Mixtures of various polyethylene glycols having melting points above the body temperature have frequently been used as a base in suppositories from which the drug is released by dissolution. Since the melting points of the macrogols increase with increasing average molecular weight, macrogols having high average molecular weights, such as "Macrogol 6000", have not previously been a natural choice as a suppository base material. Mixing a granulate of the drug with "Macrogol 6000" and compressing the mixture to suppositories by a method which is known per se for the production of tablets for oral ad¬ ministration provide the following advantages: 1) The suppositories do not melt under normal temperature conditions, but only at about 60°C. 2) The suppositories are cheaper to produce. 3) The drug can be incorporated in very high concentra¬ tions and is considerably easier to dose uniformly. 4) The product is more convenient and more pleasant to use for the patient. 5) Avoidance of drug decomposition during the heating which is necessary in traditional moulding of suppo¬ sitories. 6) It is easier to obtain and maintain a homogeneous mix¬ ture, and the risk of sedimentation is eliminated. All active drugs which lend themselves for rectal admini¬ stration may be incorporated in the suppositories produced according to the invention. One of the interesting drugs in this respect is 5-aminosalicylic acid (5-ASA), which is used particularly for the treatment of colitis ulcerosa and Crohn's disease, but which has moreover been found to be of interest for the production of suppositories for treatment of hemorrhoids. Suppositories containing 5- aminosalicylic acid are known e.g. from the EP patent application 83 775, these suppositories being produced by moulding and containing max. 500 mg of 5-aminosalicylic acid per dose unit. The suppositories of the invention may contain considerably larger amounts of 5-ASA, which is absolutely an advantage for the patient. An example of the many active drugs which may be used is steroids for various applications. In addition to a polyethylene glycol or a mixture of poly- ethylene glycols having an average molecular weight of at least 4000, preferably "Macrogol 6000", in an amount of 20-50% by weight, the suppositories produced according to the invention contain microcrystalline cellulose and/or other additives common in the production of drugs. These additives and the active drug together amount to 45-75% based on the gross weight of the suppositories. Finally, the suppositories contain one or more of the substances talc, magnesium stearate and polyvinyl pyrrolidone in an amount of 2-5% by weight. The suppositories are typically compressed to symmetrical units having an approximately elliptic longitudinal sec¬ tion, i.e. the two ends are uniform (in contrast to the ordinary "torpedo-shape" where one end is pointed while the other is blunt). The following example illustrates the invention: EXAMPLE A suppository basic mass for the production of 1000 suppo¬ sitories consists of the following ingredients: "Macrogol 6000" 572 g Microcrystalline cellulose and active drug 1000 g Magnesium stearate 4 g Talc 4 g Polyvinyl pyrrolidone + ethanol (1:19) q.s. A granulate is made from the microcrystalline cellulose, the active drug, e.g. 5-aminosalicylic acid (5-ASA) and the mixture of polyvinyl pyrrolidone and ethanol. The resulting granulate is mixed with "Macrogol 6000", and then magnesium stearate and talc are added. The granulate can then be compressed to suppositories in a tabletting machine in a manner known per se.

Claims: P a t n t C l a i m s 1. A process for producing suppositories by compression, c h a r a c t e r i z e d by producing a suppository mix¬ ture granulate containing a considerably larger amount of active drug than ordinary suppositories as well as 20-50% by weight of a polyethylene glycol having an average mole¬ cular weight of at least 4000, and then compressing the produced mass to suppositories by a method known per se for the production of tablets. 2. A process according to claim 1, c h a r a c t e r ¬ i z e d by producing a suppository mass having the following composition: polyethylene glycol: 20-50% active drug as well as microcrystalline cellulose and/or other additives common in the production of drugs: 45-75%, preferably at least 50% talc, magnesium stearate and/or polyvinyl pyrrolidone: 2-5% the stated percentages being percentages by weight. 3. A process according to claim 1 or 2, c h a r a c ¬ t e r i z e d in that the polyethylene glycol used has an average molecular weight of 6000. 4. A process according to any of the preceding claims, c h a r a c t e r i z e d in that the polyethylene glycol used is selected from "Macrogol 4000", "Macrogol 6000" and mixtures thereof. 5. Suppositories, c h a r a c t e r i z e d in that they are produced by a process according to any of claims 1-4. 6. Suppositories according to claim 5, c h a r a c - t e r i z e d in that they have the following composi¬ tion: polyethylene glycol having an average molecular weight of at least 4000: 20-50% active drug as well as microcrystalline cellulose and/or other additives common in the production of drugs: 45-75%, preferably at least 50% talc, magnesium stearate and/or polyvinyl pyrrolidone: 2-5% the stated percentages being percentages by weight. 7. Suppositories according to claim 5 or 6, c h a r a c ¬ t e r i z e d in that the polyethylene glycol used is "Macrogol 6000". 8. Suppositories according to any of claims 5-7, c h a ¬ r a c t e r i z e d in that they contain 5-aminosalicylic acid (5-ASA) as an active drug in an amount of up to 75% of the gross weight of the product. 9. Suppositories according to any of claims 5-7, c h a ¬ r a c t e r i z e d in that they contain a steroid as an active drug. AMENDED CLAIMS [received by the International Bureau on 23 October 1992 (23.10.92); original claims 1-9 replaced by amended claims 1-8 (2 pages)] 1. A process for producing suppositories by compression, c h a r a c t e r i z e d by producing a suppository mix¬ ture granulate containing 50-75% active drug as well as optionally microcrystalline cellulose and/or other addi¬ tives common in the production of drugs, 2-5% talc, magne¬ sium stearate and/or polyvinyl pyrrolidone as well as 20- 50% by weight of a polyethylene glycol having an average molecular weight of at least 4000, and compressing the produced mass to suppositories by a method known per se for the production of tablets. 2. A process according to claim 1, c h a r a c t e r ¬ i z e d in that the polyethylene glycol used has an ave¬ rage molecular weight of 6000. 3. A process according to claim 1 or 2, c h a r a c - t e r i z e d in that the polyethylene glycol used is selected from "Macrogol 4000", "Macrogol 6000" and mix¬ tures thereof. 4. Suppositories, c h a r a c t e r i z e d in that they are produced by a process according to any of claims 1-3. 5. Suppositories according to claim 4, c h a r a c ¬ t e r i z e d in that they have the following composi¬ tion: polyethylene glycol having an average molecular weight of at least 4000: 20-50% active drug as well as microcrystalline cellulose and/or other additives common in the production of drugs: 50-75% talc, magnesium stearate and/or polyvinyl pyrrolidone: 2-5% the stated percentages being percentages by weight. 6. Suppositories according to claim 4 or 5, c h a r a c ¬ t e r i z e d in that the polyethylene glycol used is "Macrogol 6000". 7. Suppositories according to any of claims 4-6, c h a ¬ r a c t e r i z e d in that they contain 5-aminosalicylic acid (5-ASA) as an active drug in an amount of up to 75% of the gross weight of the product. 8. Suppositories according to any of claims 4-6, c h a ¬ r a c t e r i z e d in that they contain a steroid as an active drug.

Inventors: HALSKOV SOEREN, HALSKOV, SOEREN
Applicants: FERRING FARMA LAB, FARMACEUTISK LABORATORIUM FERRING A/S
Application year: 1992
Main classification: A61K9
IPC codes: A61J3, A61K9, A61K47